Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings that suggest the combination of carfilzomib, dexamethasone, and daratumumab represents an efficacious new regimen for patients with relapsed or refractory disease, including those who are refractory to lenalidomide (Abstract LBA-6).

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.